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1. Preamble 43 
1.1. Need for Developing Case Definitions and Guidelines for Data Collection, Analysis, and 44 
Presentation for Dysfunctional Labor as an Adverse Event Following Immunization 45 
Vaccination during pregnancy is recommended for both maternal and neonatal benefit against a number 46 
of potential infections. The tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine is 47 
now routine recommended for pregnant women in each pregnancy not only for maternal benefit, but to 48 
confer passive antibody transfer to the newborn until infant immunizations can be given [1]. Influenza 49 
vaccinations are also strongly recommended for any pregnant woman, or women who might become 50 
pregnant during influenza seasons [2].  The safety of both these vaccinations has been well established.  51 
Efforts to develop new vaccinations for use during pregnancy represent a new opportunity to prevent 52 
common maternal and neonatal infections with severe morbidity and mortality. There is growing interest 53 
and research around maternal immunization against both Group B streptococcus (GBS) and Respiratory 54 
syncytial virus (RSV) as a public health strategy to prevent neonatal and infant infections worldwide [3, 4].  55 
 56 
Establishing the safety profile of any new vaccination requires careful surveillance of potential adverse 57 
effects and consistent terminology and definitions across context and time. The World Health 58 
Organization (WHO) defines an ‘adverse event following immunization’ (AEFI) as “any untoward medical 59 
occurrence which follows immunization and, which does not necessarily have a causal relationship with 60 
the use of the vaccine. The adverse event may be an unfavorable or unintended sign, an abnormal 61 
laboratory finding, a symptom or disease” [5]. Recognizing that vaccination is often temporally related to 62 
many events, abnormal findings or diseases, causality assessment between an AEFI and vaccination 63 
requires further rigorous assessment and study. Monitoring of a broad array of events, including those 64 
without established or suspected links to vaccine can therefore provide the initial basis for data with which 65 
such causality can be proven or disproven.  66 
 67 
Dysfunctional labor is relatively common occurrence during the intrapartum stage of pregnancy.  68 
Incidence estimates vary due to differences in definitions, but approximately 20% of labors are thought to 69 
be affected by this condition[6]. Though there are no reported links between dysfunctional labor and 70 
immunization, the measurement of this potential complication in association with vaccination is important 71 
to establish vaccine safety. Despite being relatively common, there is a lack of consensus on the criteria 72 
for the diagnosis of dysfunctional labor. Guidelines from professional obstetric societies differ in both the 73 
criteria used to define this process and when intervention should occur (Table 1.)  The Brighton 74 
Collaboration has been developing standardized definitions for use in vaccine trials since 2001[7].  To 75 
further consistent terminology and definitions of outcomes and adverse events typically reported in 76 
vaccine trials, specifically for maternal immunization, standardized definitions of common obstetric 77 
outcomes are needed. The goal of this working group was therefore to provide a case definition for this 78 
term to facilitate surveillance and case ascertainment in vaccine trials.  79 
 80 
Labor is typically divided into three stages. The first stage of labor marks the onset of labor until full 81 
dilation of the cervix; the second stage, full dilation until delivery of the fetus, and the third, delivery of the 82 
placenta. In the 1950s, Friedman first described the first stage dividing this into latent and active phases 83 
of labor [8, 9]. His work first demonstrated the broad range of labor duration experienced by women and 84 
until recently provided the basis for defining normal progress and length of labor limits of normal labor 85 
duration.  Recent evidence, however, from a larger more diverse population of women have challenged 86 
these historical durations [10]. 87 
 88 
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Dysfunctional or prolonged labor refers to prolongation in the duration of labor, typically in the first stage 89 
of labor. Diagnosis of delay in labor is dependent on careful monitoring of uterine contraction intensity, 90 
duration and frequency, cervical dilation and descent of the fetus through the pelvis. Dysfunctional labor 91 
can be an important contributor to maternal and perinatal mortality and morbidity if it remains 92 
unrecognized and untreated when needed. On the other hand, pre-emptive diagnosis of dysfunctional 93 
labor may lead to unnecessary interventions. Labor dysfunction is a leading indication for primary 94 
caesarean section and there is concern, that an over diagnosis may be a contributor to high and rising 95 
caesarean section rates [11].  96 
 97 
The pathophysiology of dysfunctional labor is multifactorial and complex and yet to be fully elucidated. 98 
Often, the exact etiology of dysfunctional labor is unknown. Broadly, etiology can be categorized into 99 
uterine contractile dysfunctions and abnormalities in the cephalopelvic ratio (i.e. the relation of the fetal 100 
size, presentation and position to the maternal pelvis).  Both these causes can be influenced by a number 101 
of genetic and environmental factors including but not limited to maternal and gestational age, pre-102 
pregnancy body mass index, pregnancy weight gain, physical activity, medical co-morbidities, parity, and 103 
obstetric complications (pre-eclampsia, premature rupture of membranes, chorio-amnionitis, placental 104 
abruption )[12-15].  105 
1.2. Methods for the Development of the Case Definition and Guidelines for Data Collection, 106 
Analysis, and Presentation for Dysfunctional Labor as an Adverse Events Following 107 
Immunization 108 
Following the process described in the overview paper [16] as well as on the Brighton Collaboration 109 
Website http://www.brightoncollaboration.org/internet/en/index/process.html, the Brighton Collaboration 110 
Dysfunctional Labor Working Group was formed in 2015 and included members of clinical, academic, 111 
public health and industry background. The composition of the working and reference group as well as 112 
results of the web-based survey completed by the reference group with subsequent discussions in the 113 
working group can be viewed at: 114 
http://www.brightoncollaboration.org/internet/en/index/working_groups.html.  115 
 116 
To guide the decision-making for the case definition and guidelines, a literature search for publications in 117 
any language was performed using Medline, Embase and the Cochrane Libraries, including the terms 118 
dysfunctional, prolonged, delayed, obstructed, abnormal, augmented labor, arrest of dilation, labor 119 
dystocia AND vaccination’ or ‘vaccine’ or ‘immunization’ OR ‘immunize’ OR ‘inoculation. The search 120 
resulted in the identification of 172 references. All abstracts were screened for possible reports of 121 
dysfunctional labor following immunization. Two full text articles with potentially relevant material were 122 
reviewed in more detail, in order to identify studies using case definitions or, in their absence, providing 123 
clinical descriptions of the case material [17, 18]. This review resulted in no articles providing case reports 124 
or case definitions of dysfunctional labor following immunization.  125 
 126 
To further guide decision-making process, guidelines from major professional obstetric societies were 127 
reviewed and definitions of dysfunctional or prolonged labor summarized and provided to members of the 128 
working group for review (Table 1).  129 
1.3. Rationale for Selected Decisions about the Case Definition of Dysfunctional Labor as an 130 
Adverse Event Following Immunization 131 
 132 
Our focus throughout this process is to provide criteria for diagnostic certainty for the purpose of case 133 
definition rather than for the identification of time frames for intervention or management changes. This is 134 
a marked difference from the definitions provided in most guidelines where a timeframe or criteria are 135 
used to suggest when intervention and management changes should occur. Thus, a case meeting the 136 
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definitions provided may or may not warrant intervention, however it is not within the purview of this 137 
working group to provide such recommendations.  138 
 139 
We recommend criteria used in case ascertainment as defined below are restricted to term singleton 140 
pregnancies, i.e. at or after 37 completed weeks and before 42 weeks of pregnancy. The pathophysiology 141 
and course of labor in preterm, previable pregnancies or postdate pregnancies was felt to be sufficiently 142 
different that separate terminology and case definitions should apply. Both preterm labor and pregnancy 143 
loss have been separately defined by working groups though the Brighton collaboration [19, 20]. Despite 144 
similarities between labor in multiple vs. singleton gestations the working group felt the interaction 145 
between vaccination in a these different gestations may be different and thus warrant a separate 146 
consideration.  147 
 148 
 149 
Definitions were formed separately for both the first stage and second stage of labor. Within the first stage 150 
we choose to focus on a definition of dysfunction once the established or active labor is reached. The 151 
definitions, therefore do not address potential dysfunction or protraction of the latent phase in the first 152 
stage of labor. Established labor describes the onset of active labor, (regular contractions and a cervical 153 
dilation of 4 centimeters (cm). This is distinct from the active phase of the first stage as described by 154 
Zhang et al where there is acceleration in the rate of dilation at 6cm. This stage of cervical dilation has 155 
since been used by United States professional societies as the basis for recommendations on a point 156 
before which  unnecessary intervention should be avoided, rather than as a definition of established labor 157 
[21][[10]. Established labor was also chosen as the starting time point as it includes all labors once they 158 
are established, regardless of whether they were initially induced or spontaneous. The requirement for 159 
regular contractions and cervical dilation of at least 4cm would mean that an induced labor that begins 160 
with foley catheter cervical ripening and achieves a mechanical dilation of 4cm, but without regular 161 
contractions is not considered in established labor. Similarly a multiparous woman with a cervix dilated to 162 
4cm but without any contractions would not be considered in established labor.  163 
 164 
We chose not to include the use of regional analgesia as a separate category within our definitions for 165 
both first and second stages of labor. We recognize that during routine clinical practice, the diagnosis of 166 
dysfunctional labor and potential subsequent intervention is often adjusted in the presence of regional 167 
analgesia. Current evidence suggests no impact of regional anesthesia on the first stage[22]. We 168 
recognize literature that shows that the second stage is longer in women with regional anesthesia [22], 169 
however for the purposes of case definition the working group considered regional analgesia a risk factor 170 
for a prolonged second stage rather than warranting separate categorization. As noted above, the scope 171 
of these definitions are for case ascertainment alone and not to prescribe or prevent intervention. Thus by 172 
excluding regional anesthesia as an influence on the case definition we do not mean to suggest any 173 
change in management decisions that might occur in women who do undergo regional anesthesia.  174 
 175 
In formulating a case definition that reflects diagnostic certainty we weighed specificity versus sensitivity. 176 
After reaching consensus, only two levels of definition were formed, both of which relate to diagnostic 177 
certainty around case definition, rather than clinical severity of a case. To make the diagnosis of 178 
dysfunctional labor, an examiner capable of reliably assessing uterine contractions, amniotic membrane 179 
status (intact vs. ruptured), cervical dilation, fetal station and a measure of time is required. The case 180 
definition has been formulated such that the level one definition is highly specific for the condition. As 181 
maximum specificity normally implies a loss of sensitivity, one additional diagnostic level has been 182 
included in the definition, offering a stepwise increase of sensitivity from level one to level two, while 183 
retaining an acceptable level of specificity at all levels.  In this way it is hoped that all possible cases of 184 
dysfunctional labor can be captured. In the first stage of labor, certainty around ruptured membranes 185 
distinguishes between a level one and level two level of certainty. This second level of diagnostic 186 
certainty recognizes circumstances where the timing or certainty of rupture of membranes is unknown to 187 
the woman or her provider or is not documented in the medical record. In the second stage of labor, 188 
diagnostic certainty in level one and two are distinguished by certainty around the onset of active 189 
maternal effort i.e. pushing or visible baby after full dilation (cervix is reported at 10cm or no longer felt 190 
around the presenting part). This allows for variations in practice where women are allowed passive 191 
descent of the fetal head after full dilation or in cases where the onset of active pushing after full dilation 192 
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is not recorded. In both stages of labor, the working group determined a third level of definition would be 193 
not be specific enough to reliably measure cases of dysfunctional labor, therefore a third level of 194 
diagnostic certainty was not included.  195 
 196 
Influence of treatment on fulfillment of case definition  197 
The Working Group decided against using “treatment” or “treatment response” towards fulfillment of 198 
dysfunctional labor case definition except in the second stage of labor. No distinction is made between 199 
spontaneous, augmented or induced labors, though recognizing, that induction may represent a risk 200 
factor for labor dysfunction. Similarly in the second stage of labor, no distinction is made for labors in 201 
which women receive regional anesthesia, though as noted above, it is recognized that this might 202 
represent a risk factor for prolonged second stage. We designed both level one and two definitions to be 203 
broad enough to include cases presenting differently due to appropriate and early treatment initiation. 204 
An exception is made for intervention for delivery in the second stage of labor, either by operative vaginal 205 
delivery or caesarean delivery for the indication of failure to progress or arrest of descent. This exception 206 
was made as it was felt practice patterns exist where early intervention is performed in the second stage 207 
and exclusion of these cases could result in underreporting of dysfunctional labor. 208 
 209 
Timing post immunization 210 
Specific time frames for the onset of symptoms following immunization are not included in this definition.  211 
Due to the lack of a reported link between dysfunctional labor and immunization, and no postulated 212 
biological plausibility for a link, we felt a restrictive time interval from immunization to onset of 213 
dysfunctional labor should not be an integral part of such a definition. Furthermore, labor often occurs 214 
outside the controlled setting of a clinical trial or hospital. In some settings it may be impossible to obtain 215 
a clear timeline of the event, particularly in less developed or rural settings. In order to avoid selecting 216 
against such cases, the Brighton Collaboration case definition avoids setting arbitrary time frames. 217 
Therefore, we recommend that details of this interval should be assessed and reported as described in 218 
the data collection guidelines. 219 
1.4. Guidelines for data collection, analysis and presentation 220 
As mentioned in the overview paper, the case definition is accompanied by guidelines which are 221 
structured according to the steps of conducting a clinical trial, i.e. data collection, analysis and 222 
presentation. Neither case definition nor guidelines are intended to guide or establish criteria for 223 
management of ill infants, children, or adults. Both were developed to improve data comparability. 224 
1.5. Periodic review 225 
Similar to all Brighton Collaboration case definitions and guidelines, review of the definition with its 226 
guidelines is planned on a regular basis (i.e. every three to five years) or more often if needed. 227 
 228 
2. CASE DEFINITION OF Dysfunctional Labor 229 
 230 
1. First Stage of Labor 231 
For both levels of diagnostic certainty, the woman is in established labor defined by regular contractions 232 
and cervical dilation of at least 4cm.  233 
Level 1 of diagnostic certainty 234 
 235 
Progress of less than 0.5 cm cervical dilation per hour, for at least 4 hours
1
, in women in established labor  236 
(i.e. have regular contractions and cervical dilation of at least 4cm) and with confirmed ruptured 237 
membranes
2
.  238 
                                               
1 “For at least 4 hours” was added to ensure adequate time allowed for progression. Thus a case where progression is less than 
0.5cm in the first hour, but then subsequently speeds up would not meet the criteria for delayed or dysfunctional labor. It must 
be less than 0.5cm/hour averaged over 4 hours.  
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 239 
Level 2 of diagnostic certainty 240 
Progress of less than 0.5cm cervical dilation per hour in women, for at least 4 hours, with established 241 
labor, (i.e. that is, regular contractions and cervical dilation of at least 4cm) without certainty of ruptured 242 
membranes.  243 
 244 
2. Second Stage of Labor 245 
Level 1 of diagnostic certainty 246 
Nulliparous women: 247 
Full dilation
3
 of the cervix  248 
AND  249 
onset of the active stage (active maternal effort (i.e. pushing) OR visible baby)  250 
AND 251 
 greater than 2 hours of pushing  252 
OR use of instrument delivery for the indication of dystocia
 4,5
  253 
OR caesarean delivery for the indication of dystocia
5
 254 
 255 
Mutiparous women: 256 
Full dilation of the cervix  257 
AND  258 
onset of the active stage (active maternal effort (i.e. pushing) OR visible baby)  259 
AND 260 
greater than 1 hour of pushing  261 
OR use of instrument delivery for the indication of dystocia
4,5
 262 
OR caesarean delivery for the indication of dystocia
5
 263 
 264 
Level 2 of diagnostic certainty 265 
Nulliparous women 266 
Full dilation of the cervix in any phase of the second stage  267 
AND 268 
no delivery within 3 hours of full dilation  269 
OR use of instrument delivery for the indication of dystocia
 4,5 270 
OR caesarean delivery for the indication of dystocia
4
 271 
Multiparous women 272 
Full dilation of the cervix in any phase of the second stage  273 
AND 274 
no delivery within 3 hours of full dilation  275 
OR use of instrument delivery for the indication of dystocia
 4,5 276 
OR caesarean delivery for the indication of dystocia
4
 277 
                                                                                                                                                       
2
 Confirmed rupture of membranes is added to a level 1 of diagnostic certainty to exclude those women with 
advanced cervical exams who may have intermittent contractions but may not be in established labor.. For example, 
the multiparous woman with an advanced cervical exam.  
3
 Full dilation of the cervix is described as 10cm dilated, or no palpable cervix around the presenting part of the fetus.  
4
 Instrument delivery refers to delivery by forceps or vacuum/ventouse 
5
 Dystocia indications include arrest of descent and failure to progress as opposed to indications for fetal well-being.   
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3. GUIDELINES FOR DATA COLLECTION, ANALYSIS AND PRESENTATION OF 278 
DYSFUNCTIONAL LABOUR 279 
It was the consensus of the Brighton Collaboration Dysfunctional Labor Working Group to recommend the 280 
following guidelines to enable meaningful and standardized collection, analysis, and presentation of 281 
information about dysfunctional labor. However, implementation of all guidelines might not be possible in 282 
all settings. The availability of information may vary depending upon resources, geographical region, and 283 
whether the source of information is a prospective clinical trial, a post-marketing surveillance or 284 
epidemiological study, or an individual report of dysfunctional labor. Also, as explained in more detail in 285 
the overview paper in this volume, these guidelines have been developed by this working group for 286 
guidance only, and are not to be considered a mandatory requirement for data collection, analysis, or 287 
presentation. 288 
3.1. Data collection 289 
These guidelines represent a desirable standard for the collection of data on availability following 290 
immunization to allow for comparability of data, and are recommended as an addition to data collected for 291 
the specific study question and setting. The guidelines are not intended to guide the primary reporting of 292 
dysfunctional labor to a surveillance system or study monitor. Investigators developing a data collection 293 
tool based on these data collection guidelines also need to refer to the criteria in the case definition, 294 
which are not repeated in these guidelines.  295 
 296 
Guidelines numbers below have been developed to address data elements for the collection of adverse 297 
event information as specified in general drug safety guidelines by the International Conference on 298 
Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use [23] and 299 
the form for reporting of drug adverse events by the Council for International Organizations of Medical 300 
Sciences [24] and formulated by Jones et al[25]. These data elements include an identifiable reporter and 301 
patient, one or more prior immunizations, and a detailed description of the adverse event, in this case, of 302 
dysfunctional labor following immunization. The additional guidelines have been developed as guidance 303 
for the collection of additional information to allow for a more comprehensive understanding of 304 
dysfunctional labor following immunization. 305 
3.1.1. Source of information/reporter 306 
For all cases and/or all study participants, as appropriate, the following information should be recorded: 307 
 308 
1) Date of report. 309 
 310 
2) Name and contact information of person reporting
1
 and/or diagnosing the dysfunctional labor as 311 
specified by country-specific data protection law. 312 
 313 
3) Name and contact information of the investigator responsible for the subject, as applicable. 314 
 315 
4) Relation to the patient (e.g. Immunizer [clinician, nurse], family member [indicate relationship], other). 316 
 317 
3.1.2. Vaccine/Control 318 
3.1.2.1. Demographics 319 
For all cases and/or all study participants, as appropriate, the following information should be recorded: 320 
 321 
5) Case/study participant identifiers (e.g. first name initial followed by last name initial) or code (or in 322 
accordance with country-specific data protection laws). 323 
 324 
6) Date of birth, age, and sex.  325 
 326 
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7) For infants born to study participants: Gestational age and birth weight. 327 
3.1.2.2. Clinical and immunization history 328 
For all cases and/or all study participants, as appropriate, the following information should be recorded: 329 
 330 
8) Past medical history, including hospitalizations, underlying diseases/disorders, pre-immunization 331 
signs and symptoms including identification of indicators for, or the absence of, a history of allergy to 332 
vaccines, vaccine components or medications; food allergy; allergic rhinitis; eczema; asthma. 333 
 334 
9) Any medication history (other than treatment for the event described) prior to, during, and after 335 
immunization including prescription and non-prescription medication as well as medication or 336 
treatment with long half-life or long-term effect. (e.g. immunoglobulins, blood transfusion and 337 
immunosuppressants). 338 
 339 
10) Immunization history (i.e. previous immunizations and any adverse event following immunization 340 
(AEFI)), in particular occurrence of an adverse event after a previous immunization. 341 
 342 
3.1.3. Details of the immunization 343 
For all cases and/or all study participants, as appropriate, the following information should be recorded: 344 
 345 
11) Date and time of immunization(s). 346 
 347 
12) Description of vaccine(s) (name of vaccine, manufacturer, lot number, dose (e.g. 0.25mL, 0.5 mL, 348 
etc) and number of dose if part of a series of immunizations against the same disease). 349 
 350 
13) The anatomical sites (including left or right side) of all immunizations (e.g. vaccine A in proximal left 351 
lateral thigh, vaccine B in left deltoid).  352 
 353 
14) Route and method of administration (e.g. intramuscular, intradermal, subcutaneous, and needle-free 354 
(including type and size), other injection devices). 355 
 356 
15) Needle length and gauge. 357 
 358 
3.1.4. The adverse event 359 
16) For all cases at any level of diagnostic certainty and for reported events with insufficient evidence, the 360 
criteria fulfilled to meet the case definition should be recorded. 361 
 362 
Specifically document: 363 
 364 
17) Clinical description of signs and symptoms of dysfunctional labor and if there was medical 365 
confirmation of the event (i.e. patient seen by physician). 366 
 367 
18) Date/time of onset of established labour
2
, date/time of diagnosis of dysfunctional labor and final 368 
outcome including mode of delivery
6
. 369 
 370 
19) Time interval since immunization 371 
 372 
20) Concurrent signs, symptoms, and diseases. 373 
 374 
21) Measurement/testing 375 
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● Values and units of routinely measured parameters (e.g. temperature, blood pressure) – in 376 
particular those indicating the severity of the event; 377 
● Method of measurement (e.g. type of thermometer, oral or other route, duration of measurement, 378 
etc.); 379 
● Results of laboratory examinations, surgical and/or pathological findings and diagnoses if 380 
present. 381 
● Include documentation of time and findings for cervical exam, onset of established labor, time of 382 
initiation and duration of regional analgesia if any, full dilation, onset of maternal pushing in the 383 
second stage, and time of delivery. 384 
 385 
22) Treatment or intervention given for dysfunctional labor, especially if medication dosing, if procedure – 386 
type of procedure 387 
 388 
23) Outcome
6
 at last observation. 389 
 390 
24) Exposures other than the immunization 24 hours before and after immunization (e.g. food, 391 
environmental) considered potentially relevant to the reported event. 392 
 393 
3.1.5. Miscellaneous/ General 394 
25)  The duration of surveillance for dysfunctional labor should be predefined based on 395 
● Biologic characteristics of the vaccine e.g. live attenuated versus inactivated component 396 
vaccines;  397 
● Biologic characteristics of the vaccine-targeted disease; 398 
● Biologic characteristics of dysfunctional labor including patterns identified in previous trials (e.g. 399 
early-phase trials); and  400 
● Biologic characteristics of the vaccinee (e.g. nutrition, underlying disease like immunodepressing 401 
illness). 402 
 403 
26) The duration of follow-up reported during the surveillance period should be predefined likewise. It 404 
should aim to continue to resolution of the event, which in this case ascertainment would be after 405 
delivery is completed.  406 
 407 
27) Methods of data collection should be consistent within and between study groups, if applicable. 408 
 409 
28) Follow-up of cases should attempt to verify and complete the information collected as outlined in data 410 
collection guidelines 1 to 24. 411 
 412 
29) Investigators of patients with dysfunctional labor should provide guidance to reporters to optimize the 413 
quality and completeness of information provided. 414 
 415 
30) Reports of dysfunctional labor should be collected throughout the study period regardless of the time 416 
elapsed between immunization and the adverse event. If this is not feasible due to the study design, 417 
the study periods during which safety data are being collected should be clearly defined. 418 
 419 
3.2. Data analysis 420 
The following guidelines represent a desirable standard for analysis of data on dysfunctional labor to 421 
allow for comparability of data, and are recommended as an addition to data analyzed for the specific 422 
study question and setting. 423 
 424 
31) Reported events should be classified in one of the following five categories including the three levels 425 
of diagnostic certainty. Events that meet the case definition should be classified according to the 426 
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levels of diagnostic certainty as specified in the case definition. Events that do not meet the case 427 
definition should be classified in the additional categories for analysis. 428 
 429 
Event classification in 5 categories
8 430 
 431 
Event meets case definition  432 
1) Level 1: Criteria as specified in the on dysfunctional labor case definition 433 
2) Level 2: Criteria as specified in the on dysfunctional labor case definition  434 
 435 
Event does not meet case definition 436 
Additional categories for analysis 437 
3) Reported dysfunctional labor with insufficient evidence to meet the case definition
9
  438 
4) Not a case of dysfunctional labor 439 
 440 
32)  The interval between immunization and reported dysfunctional labor could be defined as the 441 
date/time of immunization to the date/time of onset
2
 of the first symptoms and/or signs consistent with 442 
the definition.  If few cases are reported, the concrete time course could be analyzed for each; for a 443 
large number of cases, data can be analyzed in the following increments: 444 
 445 
Subjects with dysfunctional labor by Interval to Presentation 446 
Interval* Number 
< 24h after immunization  
24h - < 72 h after immunization   
72h - <7 days after immunization  
7 days < 30 days after immunization  
More than 30 days  
TOTAL  
 447 
33) The duration of a possible dysfunctional labor could be analyzed as the interval between the 448 
date/time of the first signs consistent with the definition and the delivery of t the fetus/es
6
. Whatever 449 
start and ending are used, they should be used consistently within and across study groups.  450 
 451 
34) The distribution of data (as numerator and denominator data) could be analyzed in predefined 452 
increments (e.g. measured values, times), where applicable. Increments specified above should be 453 
used. When only a small number of cases are presented, the respective values or time course can be 454 
presented individually.  455 
 456 
35) Data on dysfunctional labor obtained from subjects receiving a vaccine should be compared with 457 
those obtained from an appropriately selected and documented control group(s) to assess 458 
background rates of hypersensitivity in non-exposed populations, and should be analyzed by study 459 
arm and dose where possible, e.g. in prospective clinical trials. Sample size to evaluate exposed 460 
versus non-exposed populations should be calculated using background rates of dysfunctional labor 461 
in the population to be studied. 462 
3.3. Data presentation 463 
These guidelines represent a desirable standard for the presentation and publication of data on 464 
dysfunctional labor following immunization to allow for comparability of data, and are recommended as an 465 
addition to data presented for the specific study question and setting. Additionally, it is recommended to 466 
refer to existing general guidelines for the presentation and publication of randomized controlled trials, 467 
systematic reviews, and meta-analyses of observational studies in epidemiology (e.g. statements of 468 
Consolidated Standards of Reporting Trials (CONSORT), of Improving the quality of reports of meta-469 
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analyses of randomized controlled trials (QUORUM), and of Meta-analysis Of Observational Studies in 470 
Epidemiology (MOOSE), respectively)[26-28]. 471 
 472 
36) All reported events of on dysfunctional labor should be presented according to the categories listed in 473 
guideline 32.  474 
 475 
37) Data on possible on dysfunctional labor events should be presented in accordance with data 476 
collection guidelines 1-24 and data analysis guidelines 31-35. 477 
 478 
38) Terms to describe on dysfunctional labor such as “low-grade”, “mild”, “moderate”, “high”, “severe” or 479 
“significant” are highly subjective, prone to wide interpretation, and should be avoided. 480 
 481 
39) Data should be presented with numerator and denominator (n/N) (and not only in percentages), if 482 
available. 483 
 484 
Although immunization safety surveillance systems denominator data are usually not readily 485 
available, attempts should be made to identify approximate denominators. The source of the 486 
denominator data should be reported and calculations of estimates be described (e.g. manufacturer 487 
data like total doses distributed, reporting through Ministry of Health, coverage/population based data, 488 
etc.).  489 
 490 
40) The incidence of cases in the study population should be presented and clearly identified as such in 491 
the text. 492 
 493 
41) If the distribution of data is skewed, median and range are usually the more appropriate statistical 494 
descriptors than a mean. However, the mean and standard deviation should also be provided.  495 
 496 
42) Any publication of data on dysfunctional labor should include a detailed description of the methods 497 
used for data collection and analysis as possible. It is essential to specify: 498 
● The study design; 499 
● The method, frequency and duration of monitoring for on dysfunctional labor; 500 
● The trial profile, indicating participant flow during a study including drop-outs and withdrawals to 501 
indicate the size and nature of the respective groups under investigation; 502 
● The type of surveillance (e.g. passive or active surveillance); 503 
● The characteristics of the surveillance system (e.g. population served, mode of report 504 
solicitation); 505 
● The search strategy in surveillance databases; 506 
● Comparison group(s), if used for analysis; 507 
● The instrument of data collection (e.g. standardized questionnaire, diary card, report form); 508 
● Whether the day of immunization was considered “day one” or “day zero” in the analysis;  509 
● Whether the date of onset
2
 and/or the date of first observation
3
 and/or the date of diagnosis
4 
was 510 
used for analysis; and  511 
● Use of this case definition for on dysfunctional labor, in the abstract or methods section of a 512 
publication
11
. 513 
 514
  515 
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 516 
Notes for guidelines 517 
1
If the reporting centre is different from the vaccinating centre, appropriate and timely communication of 518 
the adverse event should occur. 519 
2The date and/or time of onset is defined as the time post immunization, when dysfunctional labor is 520 
diagnosed. This may only be possible to determine in retrospect.  521 
3 The date and/or time of first observation of the first sign or symptom indicative for dysfunctional labor 522 
can be used if date/time of onset is not known. 523 
4
The date of diagnosis of an episode is the day post immunization when the event met the case definition 524 
at any level. 525 
5
The end of an episode is defined as the time the event no longer meets the case definition at the lowest 526 
level of the definition. 527 
6 
E.g.
 
recovery to pre-immunization health status, spontaneous resolution, therapeutic intervention, 528 
persistence of the event, sequelae, death. 529 
7
An AEFI is defined as serious by international standards if it meets one or more of the following criteria: 530 
1) it results in death, 2) is life-threatening, 3) it requires inpatient hospitalization or results in 531 
prolongation of existing hospitalization, 4) results in persistent or significant disability/incapacity, 5) is a 532 
congenital anomaly/birth defect, 6) is a medically important event or reaction. 533 
8
To determine the appropriate category, the user should first establish, whether a reported event meets 534 
the criteria for the lowest applicable level of diagnostic certainty, e.g. Level three. If the lowest 535 
applicable level of diagnostic certainty of the definition is met, and there is evidence that the criteria of 536 
the next higher level of diagnostic certainty are met, the event should be classified in the next category. 537 
This approach should be continued until the highest level of diagnostic certainty for a given event could 538 
be determined. If the lowest level of the case definition is not met, it should be ruled out that any of the 539 
higher levels of diagnostic certainty are met and the event should be classified in additional categories 540 
four or five. 541 
9
If the evidence available for an event is insufficient because information is missing, such an event should 542 
be categorized as “Reported dysfunctional labor with insufficient evidence to meet the case definition”. 543 
10
An event does not meet the case definition if investigation reveals a negative finding of a necessary 544 
criterion (necessary condition) for diagnosis. Such an event should be rejected and classified as “Not a 545 
case of dysfunctional labor”. 546 
11
Use of this document should preferably be referenced by referring to the respective    547 
 link on the Brighton Collaboration website (http://www.brightoncollaboration.org). 548 
 549 
  550 
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Table 1: Summary of Professional Guidelines 565 
 566 
Professional 
Organization 
Year 
Published 
First Stage Second Stage 
  Nulliparous Multiparous Nulliparous Multiparous 
NICE [29] 2014 Normal: 8-18hours 
Suspected delay: 
<2cm in 4 hours, 
with delay 
confirmed with 
progress of less 
than 1cm 2 hours 
later. 
Normal: 5-12 
hours 
Delay :<2cm in 4 
hours OR slowing 
in progress of 
labor 
Birth expected 
within 3 hours 
of start of active 
second stage 
Delay: 2 or more 
hours 
Birth expected 
within 2 hours of 
start of active 
stage 
Delay: 1 or more 
hours 
ACOG/SMFM 
[11] 
2014 Normal <20 hours 
Arrest: 6cm 
dilation and 4 
hours or more of 
adequate 
contractions or 6 
hours or more of 
inadequate 
contractions  
Normal < 14 hours 
Arrest: 6cm 
dilation and 4 
hours or more of 
adequate 
contractions or 6 
hours or more of 
inadequate 
contractions 
No maximum 
time frame 
Permit at least 
3 hours of 
pushing 
No maximum 
time frame. 
Permit at least 
2 hours of 
pushing 
RANZCOG [30] 2014 Prolonged if: 
<1cm/hr in active 
phase 
Prolonged if: 
<1cm/hr in active 
phase 
>2 hours >1 hour 
WHO [31] 2014 <0.5cm to 1cm/hr 
during the active 
phase 
<0.5cm to 1cm/hr 
during the active 
phase 
N/A N/A 
SOGC [32] 1995 <0.5cm/hour over 
a 4 hour period 
<0.5cm/hour over 
a 4 hour period 
2 hours if no 
regional 
anesthesia 
N/A 
FIGO [33] 2012 N/A N/A  No more than 3 
hours of active 
pushing 
No more than 2 
hour of active 
pushing 
 567 
  568 
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